Сайт использует cookie-файлы , чтобы сделать ваше пребывание на нем максимально удобным. К сайту подключен сервис веб-аналитики Яндекс Метрика, использующий cookie-файлы для анализа пользовательской активности. Вы даете согласие на обработку персональных данных с помощью этого сервиса в порядке, указанном в Политике конфиденциальности?
Venture Fund "Unicorn Biotech"
An experienced management company with a focus on developing new drugs, medical devices, and rehabilitation technologies
We not only select, but also participate in the initiation and construction of new projects
We not only select, but also participate in the initiation and construction of new projects
Venture Fund "Unicorn Biotech"
An experienced management company with a focus on developing new drugs, medical devices, and rehabilitation technologies
We not only select, but also participate in the initiation and construction of new projects
We not only select, but also participate in the initiation and construction of new projects
Request a presentation of the Unicorn Biotech Foundation
Leave a request - we will send you a presentation of the Unicorn Biotech Foundation and discuss possible cooperation.
Portfolio of our fund "PharmMed Innovations"
The investment period of our current PharmMed Innovations Fund ended on 12/19/2024, and consideration of new projects for this fund has been stopped.
Dipiaron LLC is an innovative biotech startup company. The project is aimed at creating a new original drug for the treatment of type 2 diabetes, metabolic syndrome and obesity.
Celsus is an artificial intelligence for analyzing X-ray images and CT scans. The company has been operating since 2018.
Currently, the company's products are available on the market for various areas of research by modality: mammography, chest X-ray, fluorography, computed tomography of the brain, chest CT.
All Celsus solutions are certified as a medical device in Russia and Europe (CE mark), included in the register of domestic software.
Celsus is a leader in the field of medical artificial intelligence.
In Russia, the company occupies more than 40% of the available market for medical image analysis.
Leader of the Moscow experiment on the use of artificial intelligence in radiology.
Actively works in foreign markets.
Currently, the company's products are available on the market for various areas of research by modality: mammography, chest X-ray, fluorography, computed tomography of the brain, chest CT.
All Celsus solutions are certified as a medical device in Russia and Europe (CE mark), included in the register of domestic software.
Celsus is a leader in the field of medical artificial intelligence.
In Russia, the company occupies more than 40% of the available market for medical image analysis.
Leader of the Moscow experiment on the use of artificial intelligence in radiology.
Actively works in foreign markets.
Development of a line of enzyme replacement therapy drugs for the treatment of monogenic lysosomal storage diseases with CNS manifestations.
Botkin.AI is a software platform for medical image analysis using artificial intelligence technologies. The platform solves the problem of the accuracy of identifying malignant neoplasms from CT images at early stages, refines forecasts and reduces the likelihood of human error.
Target Medicals is a biotechnology company developing an aldosterone synthase inhibitor, a novel drug for the treatment of cardiometabolic disorders caused by hypersynthesis of aldosterone, including drug-resistant hypertension, chronic heart failure, chronic kidney disease, diabetic nephropathy and other diseases.
Development of medical devices to reduce the frequency and severity of complications during mechanical ventilation
Why is venture capital important? And why in biotech?
Technological leadership begins with bold venture investments - they create an ecosystem where innovations that change the world are born
Biotech in the world is one of the leading venture industries, not inferior to IT in terms of investment volume. At the same time, in the Russian Federation there are no venture funds in the "bio" field in the investment phase
Biotech in the world is one of the leading venture industries, not inferior to IT in terms of investment volume. At the same time, in the Russian Federation there are no venture funds in the "bio" field in the investment phase
Tech Leaders That Wouldn't Have
Happened Without Venture Capital
Tech Leaders That Wouldn't Have
Happened Without Venture Capital
Focus of the new fund
“Never invest in a business you don’t understand… stay within your zone of competence.” (Warren Buffett)
That is why our focus is biotech (in the broad sense): first of all, the development of new medicines and medical devices, as well as innovative biotech solutions for the rapidly developing agricultural and food industries.
An important component of a successful project is protecting exclusivity
At the same time, during the selection process, we carefully analyze the possibilities for entry, theoretical and experimental prerequisites for an advantage - both over competitors in the market and in development - ideally, at the global level, or (at least) in the Russian Federation/EAEU market.
The project must first and foremost be aimed at solving an unmet market need.
Именно поэтому наш фокус – биотех
(в широком понимании): прежде всего, разработка новых лекарственных средств и медизделий, а также инновационные биотех-решения для бурно развивающегося с/х и пищевой индустрии
(в широком понимании): прежде всего, разработка новых лекарственных средств и медизделий, а также инновационные биотех-решения для бурно развивающегося с/х и пищевой индустрии
«Никогда не инвестируйте в бизнес, который вы не можете понять… оставайтесь в пределах своей зоны компетенции» (Уоррен Баффет).
Broad coverage, diversification
and best global practices
and best global practices
- All facets of "biotech": from pharmaceuticals and medical technology to agro- and foodtech
- From Smart Import Substitution
to Global Innovations - Investment focus: from newly created startups at the stage of scientific hypothesis to mature public companies with revenue
- Fusion of breakthrough scientific ideas
with the best evidence-based practices of the global industry - Unique tools for expanding the project funnel:
- Venture Partners Institute (= targeted support in competent startup construction)
- Unicorn Junior: pre-seed investments to test a scientific or marketing hypothesis, IP formation, etc.
- Unicorn Royalty Ventures: buyout of future royalty flow
Broad coverage, diversification
and best global practices
and best global practices
- All facets of "biotech": from pharmaceuticals and
medical technology to agro- and foodtech - From Smart Import Substitution
to Global Innovations - Investment focus: from newly created startups at the stage of scientific hypothesis to mature public companies with revenue
- Fusion of breakthrough scientific ideas
with the best evidence-based practices of the global industry - Unique tools for expanding the project funnel:
- Venture Partners Institute (= targeted support in competent startup construction)
- Unicorn Junior: pre-seed investments to test a scientific or marketing hypothesis, IP formation, etc.
- Unicorn Royalty Ventures: buyout of future royalty flow
Main criteria
Innovative (first- or best-in-class) pharmaceuticals or medical devices, as well as biotech products and technologies for agriculture or the food industry
"Smart" import-substituting products or technologies in the same areas
Focus on solving an unmet market need, at least in the Russian Federation
Scientific prerequisites for innovation or “Smart” import substitution, supported by at least preliminary experimental data
Russian legal entities, while the idea around which the startup is built can be licensed from abroad (if this is not associated with sanctions risks)
The presence of a team with relevant experience in startup development, or the willingness of the founders to strengthen it if necessary.
Protection of exclusivity, or the obvious possibility of such protection in the Russian Federation and (preferably) in the world
Project stage – almost any.
Generics, biosimilars, and other direct “copies” of existing products and technologies for which the exclusivity protection period has expired
Developments with a history of multiple failures and insufficient scientific evidence to support the viability of new approaches
General diagnostic tests, including genetic ones, do not allow scientifically based adjustments to further treatment tactics
Any developments that do not meet the requirements of scientific evidence: homeopathy, dietary supplements, general health medical equipment, entertainment diagnostics, biohacking, etc.
Projects with expected IRR less than 30%
The implementation of the project is associated with sanctions risks
Platform technologies without at least one product that has experimentally demonstrated its advantages over the competition
Main criteria
Innovative (first- or best-in-class) pharmaceuticals or medical devices, as well as biotech products and technologies for agriculture or the food industry
"Smart" import-substituting products or technologies in the same areas
Focus on solving an unmet market need, at least in the Russian Federation
Scientific prerequisites for innovation or “Smart” import substitution, supported by at least preliminary experimental data
Russian legal entities, while the idea around which the startup is built can be licensed from abroad (if this is not associated with sanctions risks)
The presence of a team with relevant experience in startup development, or the willingness of the founders to strengthen it if necessary.
Protection of exclusivity, or the obvious possibility of such protection in the Russian Federation and (preferably) in the world
Project stage – almost any.
Generics, biosimilars, and other direct “copies” of existing products and technologies for which the exclusivity protection period has expired
Developments with a history of multiple failures and insufficient scientific evidence to support the viability of new approaches
General diagnostic tests, including genetic ones, do not allow scientifically based adjustments to further treatment tactics
Any developments that do not meet the requirements of scientific evidence: homeopathy, dietary supplements, general health medical equipment, entertainment diagnostics, biohacking, etc.
Projects with expected IRR less than 30%
The implementation of the project is associated with sanctions risks
Platform technologies without at least one product that has experimentally demonstrated its advantages over the competition
Interested in biotech and investing in the future? Request a presentation from the Unicorn Biotech Foundation
Submit request
Navigation
For all questions:
Сообщение об успешной отправке!